Merck & Co., Inc. Cost of Revenue
Merck & Co., Inc. (MRK) reported Cost of Revenue of $4.39 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-07
- Merck & Co., Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $4.39B, a 23.56% increase year-over-year.
- Merck & Co., Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $4.20B, a 22.70% increase year-over-year.
- Merck & Co., Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $5.55B, a 45.01% increase year-over-year.
- Merck & Co., Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $3.85B, a 5.51% decline year-over-year.
- Merck & Co., Inc. cost of goods and services sold for fiscal 2025 was $16.38B, a 7.83% increase from fiscal 2024.
- Merck & Co., Inc. cost of goods and services sold for fiscal 2024 was $15.19B, a 5.79% decline from fiscal 2023.
- Merck & Co., Inc. cost of goods and services sold for fiscal 2023 was $16.13B, a 7.38% decline from fiscal 2022.
- Merck & Co., Inc. cost of goods and services sold for fiscal 2022 was $17.41B, a 27.78% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.39B 10-Q · filed 2026-08-07 | $8.59B 10-Q · filed 2026-08-07 | $14.14B derived: sum of 3 quarters · filed 2026-08-07 | $18.00B derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | $4.20B 10-Q · filed 2026-05-04 | $9.75B derived: sum of 2 quarters · filed 2026-05-04 | $13.60B derived: sum of 3 quarters · filed 2026-05-04 | $17.16B derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $5.55B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $9.41B derived: sum of 2 quarters · filed 2026-02-24 | $12.96B derived: sum of 3 quarters · filed 2026-08-07 | $16.38B 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $3.85B 10-Q · filed 2025-11-05 | $7.41B derived: sum of 2 quarters · filed 2026-08-07 | $10.83B 10-Q · filed 2025-11-05 | $14.66B derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $3.56B 10-Q · filed 2026-08-07 | $6.98B 10-Q · filed 2026-08-07 | $10.80B derived: sum of 3 quarters · filed 2026-08-07 | $14.88B derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | $3.42B 10-Q · filed 2026-05-04 | $7.25B derived: sum of 2 quarters · filed 2026-05-04 | $11.33B derived: sum of 3 quarters · filed 2026-05-04 | $15.07B derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | $3.83B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.91B derived: sum of 2 quarters · filed 2026-02-24 | $11.65B derived: sum of 3 quarters · filed 2026-02-24 | $15.19B 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $4.08B 10-Q · filed 2025-11-05 | $7.83B derived: sum of 2 quarters · filed 2025-11-05 | $11.37B 10-Q · filed 2025-11-05 | $15.28B derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $3.75B 10-Q · filed 2025-08-05 | $7.29B 10-Q · filed 2025-08-05 | $11.20B derived: sum of 3 quarters · filed 2026-02-24 | $15.46B derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $3.54B 10-Q · filed 2025-05-02 | $7.45B derived: sum of 2 quarters · filed 2026-02-24 | $11.72B derived: sum of 3 quarters · filed 2026-02-24 | $15.74B derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $3.91B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $8.18B derived: sum of 2 quarters · filed 2026-02-24 | $12.20B derived: sum of 3 quarters · filed 2026-02-24 | $16.13B 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $4.26B 10-Q · filed 2024-11-06 | $8.29B derived: sum of 2 quarters · filed 2024-11-06 | $12.21B 10-Q · filed 2024-11-06 | $16.09B derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $4.02B 10-Q · filed 2024-08-05 | $7.95B 10-Q · filed 2024-08-05 | $11.83B derived: sum of 3 quarters · filed 2025-02-25 | $15.77B derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $3.93B 10-Q · filed 2024-05-03 | $7.81B derived: sum of 2 quarters · filed 2025-02-25 | $11.74B derived: sum of 3 quarters · filed 2025-02-25 | $15.96B derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $3.88B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $7.82B derived: sum of 2 quarters · filed 2025-02-25 | $12.03B derived: sum of 3 quarters · filed 2025-02-25 | $17.41B 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $3.93B 10-Q · filed 2023-11-03 | $8.15B derived: sum of 2 quarters · filed 2023-11-03 | $13.53B 10-Q · filed 2023-11-03 | $17.40B derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $4.22B 10-Q · filed 2023-08-07 | $9.60B 10-Q · filed 2023-08-07 | $13.47B derived: sum of 3 quarters · filed 2024-02-26 | $16.92B derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $5.38B 10-Q · filed 2023-05-05 | $9.25B derived: sum of 2 quarters · filed 2024-02-26 | $12.70B derived: sum of 3 quarters · filed 2024-02-26 | $15.81B derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $3.87B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $7.32B derived: sum of 2 quarters · filed 2024-02-26 | $10.43B derived: sum of 3 quarters · filed 2024-02-26 | $13.63B 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $3.45B 10-Q · filed 2022-11-03 | $6.55B derived: sum of 2 quarters · filed 2022-11-03 | $9.75B 10-Q · filed 2022-11-03 | $14.78B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | $3.10B 10-Q · filed 2022-08-05 | $6.30B 10-Q · filed 2022-08-05 | $11.33B derived: sum of 3 quarters · filed 2023-02-24 | $14.35B derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | $3.20B 10-Q · filed 2022-05-05 | $3.67B 10-Q · filed 2021-05-05 | $8.23B derived: sum of 2 quarters · filed 2023-02-24 | $11.24B derived: sum of 3 quarters · filed 2023-02-24 | $13.99B derived: sum of 4 quarters · filed 2023-02-24 | |||
| 2020-12-31 | $5.03B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $8.04B derived: sum of 2 quarters · filed 2023-02-24 | $10.79B derived: sum of 3 quarters · filed 2023-02-24 | $13.62B 10-K · filed 2023-02-24 | $15.48B 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $3.01B 10-Q · filed 2021-11-05 | $3.48B 10-Q · filed 2020-11-05 | $5.76B derived: sum of 2 quarters · filed 2021-11-05 | $8.59B 10-Q · filed 2021-11-05 | $9.95B 10-Q · filed 2020-11-05 | $10.64B derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-06-30 | $2.75B 10-Q · filed 2021-08-09 | $3.16B 10-Q · filed 2020-08-05 | $5.58B 10-Q · filed 2021-08-09 | $6.47B 10-Q · filed 2020-08-05 | $7.63B derived: sum of 3 quarters · filed 2022-02-25 | $11.62B derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-03-31 | $3.31B 10-Q · filed 2021-05-05 | $4.88B derived: sum of 2 quarters · filed 2022-02-25 | $8.88B derived: sum of 3 quarters · filed 2022-02-25 | $12.28B derived: sum of 4 quarters · filed 2022-02-25 | ||||
| 2019-12-31 | $1.57B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $5.56B derived: sum of 2 quarters · filed 2022-02-25 | $8.96B derived: sum of 3 quarters · filed 2022-02-25 | $12.02B 10-K · filed 2022-02-25 | $14.11B 10-K · filed 2020-02-26 | |||
| 2019-09-30 | $3.99B 10-Q · filed 2020-11-05 | $7.39B derived: sum of 2 quarters · filed 2020-11-05 | $10.44B 10-Q · filed 2020-11-05 | $13.73B derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $3.40B 10-Q · filed 2020-08-05 | $6.45B 10-Q · filed 2020-08-05 | $9.74B derived: sum of 3 quarters · filed 2021-02-25 | $13.36B derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $3.05B 10-Q · filed 2020-05-06 | $6.34B derived: sum of 2 quarters · filed 2021-02-25 | $9.96B derived: sum of 3 quarters · filed 2021-02-25 | $13.38B derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $3.29B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $6.91B derived: sum of 2 quarters · filed 2021-02-25 | $10.32B derived: sum of 3 quarters · filed 2021-02-25 | $13.51B 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $3.62B 10-Q · filed 2019-11-05 | $7.04B derived: sum of 2 quarters · filed 2019-11-05 | $10.22B 10-Q · filed 2019-11-05 | $13.66B derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-06-30 | $3.42B 10-Q · filed 2019-08-06 | $6.60B 10-Q · filed 2019-08-06 | $10.04B derived: sum of 3 quarters · filed 2020-02-26 | $13.35B derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-03-31 | $3.18B 10-Q · filed 2019-05-08 | $6.62B derived: sum of 2 quarters · filed 2020-02-26 | $9.93B derived: sum of 3 quarters · filed 2020-02-26 | $13.05B derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2017-12-31 | $3.44B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $6.75B derived: sum of 2 quarters · filed 2020-02-26 | $9.86B derived: sum of 3 quarters · filed 2020-02-26 | $12.91B 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | $3.31B 10-Q · filed 2018-11-06 | $6.42B derived: sum of 2 quarters · filed 2018-11-06 | $9.47B 10-Q · filed 2018-11-06 | |||||
| 2017-06-30 | $3.12B 10-Q · filed 2018-08-07 | $6.17B 10-Q · filed 2018-08-07 | ||||||
| 2016-12-31 | $14.03B 10-K · filed 2019-02-27 | |||||||
| 2009-09-30 | $1.72B 10-Q · filed 2009-10-29 | $3.34B derived: sum of 2 quarters · filed 2009-10-29 | $4.74B 10-Q · filed 2009-10-29 | |||||
| 2009-06-30 | $1.62B 10-Q · filed 2009-07-24 | $3.02B 10-Q · filed 2009-07-24 | ||||||
| 2008-09-30 | $1.74B 10-Q · filed 2009-10-29 | $3.65B derived: sum of 2 quarters · filed 2009-10-29 | $5.78B 10-Q · filed 2009-10-29 | |||||
| 2008-06-30 | $1.91B 10-Q · filed 2009-07-24 | $4.04B 10-Q · filed 2009-07-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |